Gossamer Bio Inc. 已正式确定其2030年到期的7.50%可转换优先有担保第一留置权票据的转换比率,并同时公布了相关购股权证的行权价格。此举标志着公司融资工具关键条款的最终敲定,为投资者提供了明确的转换与行权依据。
Gossamer Bio Inc. 已正式确定其2030年到期的7.50%可转换优先有担保第一留置权票据的转换比率,并同时公布了相关购股权证的行权价格。此举标志着公司融资工具关键条款的最终敲定,为投资者提供了明确的转换与行权依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.